Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)
Latest Information Update: 11 Jan 2025
At a glance
- Drugs Gemcitabine (Primary) ; Natural killer cell therapy (Primary) ; Naxitamab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DiG NKs
Most Recent Events
- 08 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
- 08 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.
- 13 Dec 2024 Planned number of patients changed from 42 to 45.